AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2673438
Drug: Monthly three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly three day course with adriamycin (ADM), cyclophosphamide (CPM), vindesine (VDS) and 5 fluoro‐uracil (5 FU)
Trial: 2673438
Drug: Fractionated schedule
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated schedule with 4 injections of ADM, CPM, VDS and continuous infusion of 5 FU over 10 days
Trial: 22392354
Drug: Lichtenstein technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lichtenstein technique (L)
Trial: 19672152
Drug: gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine plus LY293111 (LY) 600 mg twice daily
Trial: 17502466
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal system (2, 4, or 6 mg during 24 hours for 24 weeks)
Trial: 21080009
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal system
Trial: 15031343
Drug: Alfacalcidol treatment
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol treatment
Trial: 12153335
Drug: Ziprasidone 80
RxNorm normalized name: ziprasidone 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 80 or 160 mg/day
Trial: 12153335
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 to 160 mg/day
Trial: 12153335
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral ziprasidone treatment
Trial: 9222908
Drug: Ulnar L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulnar L incision
Trial: 3665218
Drug: Isosorbide-5-mononitrate (ISMN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (ISMN) 40 mg
Trial: 8699777
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 40 mg
Trial: 30357437
Drug: Ketamine (subanesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (subanesthetic dose, target plasma level 100 ng/ml)
Trial: 23674608
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rifampicin
Trial: 23674608
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rifampicin
Trial: 23674608
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rifampicin
Trial: 19767711
Drug: Psychiatric drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric drug therapy in addition to topical corticosteroids
Trial: 19767711
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids only (Control)
Trial: 19767711
Drug: Psychiatric drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric drug therapy
Trial: 16553140
Drug: Psychosocial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial therapy (PST; physical activity control) 3 times/wk for 12 weeks
Trial: 12692051
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg twice daily (n=259)
Trial: 11083356
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity laser therapy (1.06-microm continuous wave laser emitting 204 mW/cm2 for 60 seconds at 7 points along the symptomatic forearm, 3 times weekly for 4 weeks)
Trial: 11083356
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (inactive laser treatment)
Trial: 11083356
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity laser therapy
Trial: 24447183
Drug: HTNV DNA
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTNV DNA vaccine (2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Trial: 24447183
Drug: PUUV DNA
RxNorm normalized name: PUUV DNA vaccine
DrugBank: Puumala virus DNA vaccine (DB17809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUUV DNA vaccine (2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Trial: 24447183
Drug: Combined HTNV
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HTNV and PUUV DNA vaccines (1.0 mg each, 2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Trial: 19762206
Drug: Combined Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Therapy (PTA + SEP)
Trial: 27630092
Drug: Four implants
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four implants
Trial: 27630092
Drug: Six implants
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six implants
Trial: 25536639
Drug: TVR-standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVR-standard group (2,250 mg TVR for 12 weeks plus reduced ribavirin dose)
Trial: 25536639
Drug: TVR-reduced group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVR-reduced group (1,500 mg TVR plus standard ribavirin dose)
Trial: 21481003
Drug: New gustatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New gustatory stimulant of salivary secretion (GSSS) containing weaker malic acid, fluoride, and xylitol
Trial: 21481003
Drug: Traditional citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional citric acid-based gustatory stimulant of salivary secretion (GSSS)
Trial: 10714690
Drug: Combination cyclopentolate
RxNorm normalized name: cyclopentolate, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cyclopentolate 0.2% and phenylephrine 1% eyedrops
Trial: 1576488
Drug: 100 IU
RxNorm normalized name: Vitamin E 100 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU of salmon calcitonin and 500 mg of elemental calcium for 10 consecutive days each month
Trial: 1576488
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of elemental calcium only for 10 consecutive days each month
Trial: 30982716
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication (paracetamol, opioids, or both)
Trial: 27041272
Drug: Subtenon block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtenon block with mixture of 4 mL of 2% lidocaine and 0.5% bupivacaine (50:50)
Trial: 27041272
Drug: Subtenon injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtenon injection of saline
Trial: 23996878
Drug: Postoperative intensity‐modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative intensity‐modulated radiation therapy (IMRT)
Trial: 22499521
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide intramuscular injection after swallowing the capsule
Trial: 22499521
Drug: No metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No metoclopramide administered (Control)
Trial: 22499521
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide intramuscular injection
Trial: 20727717
Drug: Focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused treatment groups (various interventions)
Trial: 20727717
Drug: Control UHR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control UHR groups (no treatment or treatment as usual)
Trial: 20727717
Drug: Any focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any focused treatment
Trial: 16199148
Drug: Formoterol 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 9 microg bid plus terbutaline 0.5 mg as needed (FORM bid)
Trial: 16199148
Drug: Placebo bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid plus terbutaline 0.5 mg as needed (placebo)
Trial: 10626340
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + complex of amino acids (100 mg 3 times a day sublingually)
Trial: 10626340
Drug: Adjuvant preductal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant preductal (20 mg 3 times a day per os for 20 days)
Trial: 10626340
Drug: Conventional antianginal
RxNorm normalized name: ANTIANGINALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antianginal therapy (nitrates, beta-adrenoblockers, calcium antagonists, diuretics, ACI inhibitors, cardiac glycosides, and aspirin)
Trial: 23383726
Drug: Group counseling
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group counseling intervention (problem-solving therapy approach)
Trial: 15598478
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination latanoprost 0.005% + timolol maleate 0.5% QD
Trial: 11121915
Drug: ABT-229 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 1.25 mg
Trial: 11121915
Drug: ABT-229 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 2.5 mg
Trial: 11121915
Drug: ABT-229 5
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 5 mg
Trial: 11121915
Drug: ABT-229 10
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 10 mg
Trial: 8173702
Drug: Diltiazem (180-360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180-360 mg daily)
Trial: 8173702
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (diuretics or beta-adrenergic blockers)
Trial: 3507007
Drug: Beef extended
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef extended with soy products fortified with 60 mg Fe and 25 mg Zn/100 g protein
Trial: 29534403
Drug: Regular dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dosage of fasudil (30 mg)
Trial: 29534403
Drug: Large dosage
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large dosage of fasudil (60 mg)
Trial: 29534403
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between large dosage and regular dosage groups
Trial: 26603174
Drug: Artesunate-mefloquine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine)
Trial: 26603174
Drug: Chloroquine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (target dose 25 mg/kg)
Trial: 16962170
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin users
Trial: 16962170
Drug: Regular acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular acetaminophen users
Trial: 16962170
Drug: Greater frequency
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater frequency of acetaminophen use (>7 tablets weekly)
Trial: 16962170
Drug: Greater duration
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater duration of acetaminophen use (>10 years)
Trial: 20689457
Drug: 6.4% carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% carbohydrate‐electrolyte solution (CHO)
Trial: 7604806
Drug: Fluvastatin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin at 20 mg twice daily
Trial: 7604787
Drug: Gemfibrozil at
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil at 600 mg twice daily
Trial: 7604787
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluvastatin and gemfibrozil
Trial: 2123072
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) administered within 4 hours from symptom onset (group A)
Trial: 2123072
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) administered between 4 and 8 hours from symptom onset (group B)
Trial: 360249
Drug: Carbamazepine (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (300-600 mg daily for six weeks)
Trial: 31324444
Drug: Thymoglobulin induction
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin induction with tacrolimus and/or mycophenolate mofetil maintenance, steroids not used beyond 1 week
Trial: 16116596
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist treatment
Trial: 20150283
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CON)
Trial: 10419922
Drug: Methotrexate 7.5
RxNorm normalized name: methotrexate 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 7.5 mg/wk
Trial: 2186776
Drug: Papaverine 100
RxNorm normalized name: papaverine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine 100 mg q.d.s. orally for 4 weeks
Trial: 28162984
Drug: Eltrombopag (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (50 mg to 300 mg)
Trial: 16278621
Drug: Group education
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group education and an educational booklet on the first day of therapy, counseling in the third and sixth months
Trial: 12036860
Drug: Idarubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin plus continuous-infusion, high-dose cytosine arabinoside (IA)
Trial: 7000222
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (300 mg intramuscularly per week)
Trial: 7000222
Drug: Oestradiol undecylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol undecylate (100 mg intramuscularly per month)
Trial: 9722227
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate 0.1 mg o.d. (n=26)
Trial: 9722227
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate 0.2 mg o.d. (n=25)
Trial: 8036306
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no inhaled steroids)
Trial: 2730826
Drug: Undiluted i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undiluted i.m. preparation (25 mg ml‐1)
Trial: 2730826
Drug: Diluted i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted i.m. preparation in normal saline (5 mg ml‐1)
Trial: 16091396
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg/6 weeks)
Trial: 10676476
Drug: Selenium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium concentration in serum (55 +/- 11 micrograms Se/L)
Trial: 10676476
Drug: Selenium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium concentration in hair (0.268 +/- 0.040 microgram Se/g)
Trial: 10676476
Drug: Selenium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium concentration in urine (12 +/- 5 micrograms Se/L)
Trial: 7573869
Drug: Different end-tidal
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different end-tidal carbon dioxide and volatile agent concentrations during maintenance of anaesthesia
Trial: 29756749
Drug: Flurbiprofen oral
RxNorm normalized name: flurbiprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen oral spray
Trial: 29756749
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride oral spray
Trial: 27115264
Drug: Quality improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality improvement intervention including daily checklist and goal setting during multidisciplinary rounds with follow‐up clinician prompting for 11 care processes
Trial: 25214161
Drug: Nutritional education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional education and supplemental iron administration (iron polymaltose complex)
Trial: 25214161
Drug: Iron medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron medication for >6 months
Trial: 17285386
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg after induction of anesthesia
Trial: 17285386
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg just before the end of anesthesia
Trial: 17285386
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg after induction of anesthesia and Metoclopramide 10 mg before the end of anesthesia
Trial: 16583989
Drug: Standard Antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Antibiotic Therapy (SAT) combined with amikacin
Trial: 16583989
Drug: Other Antibiotic
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Antibiotic Therapy (OAT) combined with amikacin
Trial: 16583989
Drug: Amikacin used
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin used in high once daily dose (HODD) with SAT or OAT
Trial: 16583989
Drug: Direct costs
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct costs of treatment with SAT
Trial: 16583989
Drug: Direct costs
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct costs of treatment with OAT
Trial: 16583989
Drug: Overall cost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall cost reduction by introducing safe and cheap standard treatment
Trial: 815188
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 500 mg
Trial: 1600043
Drug: Micronutrient antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient antioxidant therapy (600 micrograms organic selenium, 9000 i.u. beta-carotene, 0.54 g vitamin C, 270 i.u. vitamin E, 2 g methionine)
Trial: 2103755
Drug: Micronutrient antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient antioxidant therapy
Trial: 30871594
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 28 ± 2 days
Trial: 30643068
Drug: Fluvoxamine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine combined with extended-release methylphenidate (MPH-ER)
Trial: 27789196
Drug: Local consolidative
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local consolidative therapy (chemo/radiotherapy or resection of all lesions)
Trial: 27789196
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment alone (could be observation)
Trial: 22722530
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly every 12 weeks for 24 weeks
Trial: 22722530
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive (OC) pills (ethinyl estradiol 0.03 mg and gestodene 0.075 mg) daily for 24 weeks
Trial: 10974616
Drug: Cholecystokinin tetrapeptide
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin tetrapeptide (CCK‐4) injection, high doses, specific dosage not mentioned, duration not mentioned.
Trial: 1611113
Drug: Interferon (IFN)‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)‐alpha 2b (50 MU dose), intravesical therapy for 10 months, starting 21 days after TUR, once a week for 8 weeks, then once every 15 days for 4 months, and finally once a month for 4 months.